Pfizer forecasts 2026 profit below expectations on lower Covid product sales
Pfizer has rolled out a sweeping cost reduction programme in response to the drop in Covid-19 sales Pfizer on Tuesday ...
Pfizer has rolled out a sweeping cost reduction programme in response to the drop in Covid-19 sales Pfizer on Tuesday ...
Pfizer is looking to sell its remaining stake in Covid-19 vaccine partner BioNTech, a remnant from one of the pandemic’s ...
Pfizer raised its 2025 profit forecast for the second time this year, as ongoing cost cuts helped make up for ...
Pfizer on Friday (Oct 31) filed a lawsuit against Metsera and Novo Nordisk, saying Metsera breached its merger agreement obligations ...
Activist investor Starboard Value has taken a stake of about US$1 billion in Pfizer and is seeking to spur a ...
Pfizer also expects full-year revenue of US$3.5 billion from its antiviral drug, Paxlovid, which is used in high-risk Covid casesPfizer, ...
The decision is a blow to GSK, which is locked in fierce competition with Pfizer to corner the new market ...
PFIZER lifted its annual profit forecast on Wednesday (May 1), banking on cost cuts and better-than-expected demand for its Covid ...
GlaxoSmithKline sued Pfizer and BioNTech in Delaware federal court on Thursday (Apr 25), accusing them of infringing GSK patents related ...
A medical worker administers a dose of the "Cominarty" Pfizer-Bivalent coronavirus disease (COVID-19) vaccine to a patient at a vaccination ...
The NY Journals pride themselves on assembling a proficient and dedicated team comprising seasoned journalists and editors. This collective commitment drives us to provide our esteemed readership with nothing short of the most comprehensive, accurate, and captivating news coverage available.
Transcending the bounds of New York City to encompass a broader scope, we ensure that our audience remains well-informed and engaged with the latest developments, both locally and beyond.
© 2025 The New York Journals. All Rights Reserved.